Sonnet BioTherapeutics Provides Fiscal Year 2025 First Quarter Business and Earnings Update
Portfolio Pulse from
Sonnet BioTherapeutics has completed the dose escalation phase of its SON-1010 monotherapy in a Phase 1 trial, with promising results showing stable disease in 48% of patients and a partial response in one patient.
February 13, 2025 | 1:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Sonnet BioTherapeutics completed the dose escalation phase of its SON-1010 monotherapy in a Phase 1 trial, showing stable disease in 48% of patients and a partial response in one patient.
The completion of the dose escalation phase with positive results in a Phase 1 trial is a significant milestone for Sonnet BioTherapeutics. The stable disease in 48% of patients and a partial response in one patient suggest potential efficacy of SON-1010, which could positively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100